Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE)
Health Care · Biotechnology · US
$—
— today · — 1Y
Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Concert Pharmaceuticals, Inc. across four factors: quality 35/100, growth 0/100. Its strongest factor is quality.
CNCE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $32.04M
- P/E
- —
- EPS
- -3.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 64
- Next earnings
- —
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. functions as a biopharmaceutical firm in the clinical development phase, concentrating on the creation of innovative small-molecule therapeutics designed to address autoimmune conditions. Its primary investigational drug, CTP-543, is currently progressing through late-stage (Phase III) clinical trials for the treatment of alopecia areata, a serious autoimmune dermatological ailment. The company maintains strategic alliances with several partners, including Avanir Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Cipla Technologies, and Processa Pharmaceuticals. Established in 2006, the organization's corporate headquarters are situated in Lexington, Massachusetts.
- ISIN
- US2060221056
- Founded
- 2006
- Listed since
- Feb 13, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.77 | +2.07% |
Figures last refreshed Aug 18, 2026.